Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dactinomycin
Drug ID BADD_D00571
Description A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)
Indications and Usage For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen
Marketing Status Prescription; Discontinued
ATC Code L01DA01
DrugBank ID DB00970
KEGG ID D00214
MeSH ID D003609
PubChem ID 457193
TTD Drug ID D0P8IV
NDC Product Code 67457-928; 42658-008; 67457-513; 68254-0017; 58623-0098; 66993-489; 68305-200; 55292-811; 71288-129; 39822-2100
Synonyms Dactinomycin | Meractinomycin | Actinomycin D | Actinomycin | Cosmegen | Cosmegen Lyovac | Lyovac, Cosmegen | Lyovac-Cosmegen | Lyovac Cosmegen | LyovacCosmegen
Chemical Information
Molecular Formula C62H86N12O16
CAS Registry Number 50-76-0
SMILES CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(= C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC 6=O)C(C)C)C)C)C(C)C)C)N)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Drug dependenceUrokinase-type plasminogen activatorP00749T1775810967551; 9133674; 1734031
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abortion18.01.01.0010.000533%Not Available
Acne23.02.01.001--Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.000278%Not Available
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anaemia01.03.02.0010.000533%
Aplastic anaemia01.03.03.002--Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Blood lactate dehydrogenase increased13.04.02.0020.000139%
Body temperature increased13.15.01.001--Not Available
Cardiac failure02.05.01.0010.000208%
Cheilitis23.03.03.025; 07.05.01.001--
Chills15.05.03.016; 08.01.09.001--
Coagulopathy01.01.02.001--Not Available
Death08.04.01.001--
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000347%
Dysphagia07.01.06.003--
Encephalopathy17.13.02.0010.001066%
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Extravasation08.01.03.008--Not Available
Fatigue08.01.01.002--
Febrile neutropenia01.02.03.002; 08.05.02.004--
Feeling abnormal08.01.09.014--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages